Global Biosimilar Market Growth (Status and Outlook) 2025-2031

The global Biosimilar market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.

Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilar, must maintain consistent quality and clinical performance throughout their lifecycle.

In this report is a biologic defined as proteins, peptides, hormones or antibody’s drugs production by bio-engineered technology, but does not include a vaccine.

China’s core biosimilar players include Qilu Pharmaceutical, Shanghai Henlius and 3SBIO etc. The top 3 companies only hold a share about 61%.

In terms of product, biosimilar monoclonal antibodies is the largest segment, with a share about 85%. And in terms of application, the largest application is cancer，with a share about 50%.

LPI (LP Information)' newest research report, the “Biosimilar Industry Forecast” looks at past sales and reviews total world Biosimilar sales in 2024, providing a comprehensive analysis by region and market sector of projected Biosimilar sales for 2025 through 2031. With Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar market by product type, application, key players and key regions and countries.

Segmentation by Type:

Biosimilar Monoclonal Antibodies

Biosimilar Insulin

Others

Segmentation by Application:

Cancer

Immunological Diseases

Diabetes

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Qilu Pharmaceutical

Bio-Thera

Zhejiang Hisun

Shanghai Henlius

Innovent Biologics

Jiangsu Hengrui

Gan&Lee

Tonghua Dongbao

United Laboratory

3SBIO

Luye Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.